Immunomodulators

Patent metadata

Field	Value
Publication number	US-9856292-B2
Application number	US-201514938327-A
Country	US
Kind code	B2
Filing date	Nov 11, 2015
Priority date	Nov 14, 2014
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

First claim

What is claimed is:

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein:
A is

wherein:

denotes the point of attachment to the carbonyl group and denotes the point of attachment to the nitrogen atom;
m is 1;
w is 0, 1, or 2;
R 14 and R 15 are hydrogen;
R 16a is hydrogen;
R 16 is selected from
—CH 2 C(O)NHCH(R 17 )C(O)NH 2 ;
—CH 2 C(O)NHCH(R 17 )C(O)NHCH(R 17a )C(O)NH 2 ; and
—CH 2 C(O)NHCH(R 17 )CO 2 H;
wherein:
X is selected from
—(CH 2 ) 2 CH(CO 2 H)NHC(O)(CH 2 ) p ;
—(CH 2 CH 2 O) q ; and
—(CH 2 CH 2 O) q CH 2 CH 2 NHC(O)CH 2 CH 2 CH(CO 2 H)NHC(O)(CH 2 ) p ;
wherein q is 3, 4, 5, 6, 7, 8, 9, 10, or 11; and
wherein p is 14, 15, or 16;
each R 17a is independently selected from hydrogen and —CH 2 CO 2 H,
each R 17 is —(CH 2 ) z -triazolyl-X—R 35 , wherein z is 1 and R 35 is selected from —CO 2 H and CH 3 ,
R c , R f , R h , R i , R m , and R n are hydrogen;
R a , R e , and R j , are hydrogen;
R b , R k , and R l are methyl;
R 1 is phenylC 1 -C 3 alkyl wherein the phenyl part is optionally substituted with hydroxy, halo, or methoxy;
R 2 is C 1 -C 7 alkyl;
R 3 is amidoC 1 -C 3 alkyl or carboxyC 1 -C 3 alkyl;
R 4 and R d , together with the atoms to which they are attached, form a pyrrolidine ring;
R 5 is selected from imidazolylC 1 -C 3 alkyl, aminoC 1 -C 3 alkyl, and aminobutyl;
R 6 is selected from amidoC 1 -C 3 alkyl, aminoC 1 -C 3 alkyl, aminobutyl, and C 1 -C 7 alkyl;
R 7 and R g , together with the atoms to which they are attached, form a pyrrolidine ring optionally substituted with hydroxy;
R 8 and R 10 are indolylC 1 -C 3 alkyl optionally substituted with carboxyC 1 -C 3 alkyl;
R 9 is hydroxyC 1 -C 3 alkyl or aminoC 1 -C 3 alkyl;
R 11 is C 1 -C 7 alkyl;
R 12 is C 1 -C 7 alkyl; and
R 13 is selected from C 1 -C 7 alkyl, carboxyC 1 -C 3 alkyl, and —(CH 2 ) 3 NHC(NH)NH 2 .

2. A compound which is

or a pharmaceutically acceptable salt thereof.

3. A compound which is

or a pharmaceutically acceptable salt thereof.

4. A compound which is

or a pharmaceutically acceptable salt thereof.

5. A compound which is

or a pharmaceutical acceptable salt thereof.

6. A compound which is

or a pharmaceutically acceptable salt thereof.

7. A compound which is

or a pharmaceutically acceptable salt thereof.

8. A compound which is

or a pharmaceutically acceptable salt thereof.

9. A compound which is

or a pharmaceutically acceptable salt thereof.

10. A compound which is

or a pharmaceutically acceptable salt thereof.

11. A compound which is

or a pharmaceutically acceptable salt thereof.

12. A compound which is

or a pharmaceutically acceptable salt thereof.

13. A compound which is

or a pharmaceutically acceptable salt thereof.

14. A compound which is

or a pharmaceutically acceptable salt thereof.

15. A compound which is

or a pharmaceutically acceptable salt thereof.

16. A compound which is

or a pharmaceutically acceptable salt thereof.

17. A compound which is

or a pharmaceutically acceptable salt thereof.

18. A compound which is

or a pharmaceutically acceptable salt thereof.

19. A compound which is

or a pharmaceutically acceptable salt thereof.

20. A compound which is

or a pharmaceutically acceptable salt thereof.

21. A compound which is

or a pharmaceutically acceptable salt thereof.

22. A compound which is

or a pharmaceutically acceptable salt thereof.

23. A compound which is

or a pharmaceutically acceptable salt thereof.

24. A compound which is

or a pharmaceutically acceptable salt thereof.

25. A compound which is

or a pharmaceutically acceptable salt thereof.

26. A compound which is

or a pharmaceutically acceptable salt thereof.

27. A compound which is

or a pharmaceutically acceptable salt thereof.

28. A compound which is

or a pharmaceutically acceptable salt thereof.

29. A compound which is

or a pharmaceutically acceptable salt thereo

Assignees

• Bristol Myers Squibb Co

Inventors

• Gillman Kevin W
• Goodrich Jason
• Boy Kenneth M
• Zhang Yunhui
• Mapelli Claudio
• Poss Michael A
• Scola Paul Michael
• Langley David R
• Meanwell Nicholas A

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/18

  for HIV · CPC title